Company news
Telo Genomics Corp. (TSXV:TELO) news
Telo Genomics Corp. news releases on 6ix. Latest, Jan 30, 2024: Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
Press releases — page 2
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
January 30, 2024
Telo Genomics Gears up for American Society of Hematology Conference
December 6, 2023
Telo Genomics Launches Physician Experience Program in the United States
November 16, 2023
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
November 7, 2023
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting
November 1, 2023
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
October 26, 2023
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved
October 17, 2023
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
October 12, 2023
Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation
September 6, 2023
Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
August 29, 2023
Telo Genomics Announces Agreement for Strategic Advisory Services
June 30, 2023
Telo Genomics Completes Oversubscribed Private Placement
June 14, 2023
Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023
June 12, 2023
Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000
June 6, 2023
Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023
June 5, 2023
Telo Genomics Announces Private Placement of Units
May 19, 2023
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology Congress
May 4, 2023
Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting
April 13, 2023
Telo Genomics Advances to Final Stage of Achieving ISO Certification
March 15, 2023
Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual Meeting
February 22, 2023
Telo Genomics Appoints Kris Weinberg as Chief Executive Officer
December 12, 2022
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting
December 8, 2022
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma
November 9, 2022
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board
October 18, 2022
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
September 14, 2022
Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples
August 17, 2022
Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma
July 13, 2022
Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples
July 6, 2022
Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma
May 31, 2022
Telo Genomics Announces Investor Relations Agreement and Option Grants
March 15, 2022
Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test
March 7, 2022
Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies
February 3, 2022
Telo Genomics Advances Its Lead Product and Implements Automation to Its Workflow
January 19, 2022
Telo Genomics Announces OTCQB Venture Market Listing
December 7, 2021
Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress
October 13, 2021
Telo Genomics Adopts Advanced Notice Provisions in By-Laws
October 5, 2021
Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital
September 21, 2021
Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021
September 9, 2021
Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking
August 9, 2021
Telo Genomics Completes Final Tranche of Oversubscribed Private Placement
July 5, 2021
Telo Genomics Completes First Tranche of Oversubscribed Private Placement
July 2, 2021
Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients
April 29, 2021
Telo Genomics Announces AGM Voting Results and Provides Corporate Update
March 24, 2021
IIROC Trading Resumption - DXD; GSPR; KUR.H
November 30, 2018
IIROC Trading Halt - DXD
November 5, 2018
IIROC Trading Resumption - FLWR; DXD; OVO.P
September 25, 2018
IIROC Trading Halt - NVO and DXD
May 31, 2018
3D Signatures Inc. Opens the Market
November 2, 2016
IIROC Trade Halt - Plicit Capital Corp.
December 2, 2015
IIROC Trading Halt - PLP.P
January 17, 2014